Kura Oncology (KURA) Consolidated Net Income (2010 - 2026)
Kura Oncology (KURA) reported Consolidated Net Income of -$73.3 million for Q1 2026, down 27.69% year-over-year from -$101.4 million in Q1 2025, and down 137.16% on a QoQ basis from $197.4 million in Q4 2025.
Kura Oncology (KURA) has 8 years of Consolidated Net Income data on file, last reported at -$73.3 million in Q1 2026.
- Quarterly Consolidated Net Income fell 27.69% year-over-year to -$73.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$16.2 million (up 90.99% YoY) and the FY2025 annual result came in at -$297000.0, up 99.83% from the prior year.
- Consolidated Net Income slipped to -$73.3 million in Q1 2026 per KURA's latest filing, from $197.4 million in the prior quarter.
- Across five years, Consolidated Net Income topped out at $197.4 million in Q4 2025 and bottomed at -$74.1 million in Q3 2025.
- The 3-year median for Consolidated Net Income is -$54.4 million (2024), against an average of -$27.3 million.
- Peak annual rise in Consolidated Net Income reached 1247.57% in 2025, while the deepest fall reached 36.23% in 2025.
- Tracing KURA's Consolidated Net Income over 3 years: stood at -$17.2 million in 2024, then jumped by 1247.57% to $197.4 million in 2025, then sank by 137.16% to -$73.3 million in 2026.
- Per Business Quant, the three latest KURA Consolidated Net Income figures stand at -$73.3 million (Q1 2026), $197.4 million (Q4 2025), and -$74.1 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Consol Net Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | -2.99 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | -8.40 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | -14.46 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 1.03 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | -3.40 Mn |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 727.20 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 205.99 Mn |
| 10 | Kura Oncology | 801.92 Mn | 801.92 Mn | 18.00 Mn | -73.33 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -73.33 Mn |
| Dec 31, 2025 | 197.37 Mn |
| Sep 30, 2025 | -74.12 Mn |
| Jun 30, 2025 | -66.12 Mn |
| Mar 31, 2025 | -57.43 Mn |
| Dec 31, 2024 | -17.20 Mn |
| Sep 30, 2024 | -54.40 Mn |
| Jun 30, 2024 | -50.84 Mn |
| Mar 31, 2024 | -49.53 Mn |
| Dec 31, 2014 | -46,762.00 |
| Sep 30, 2014 | -6,428.00 |
| Jun 30, 2014 | -6,887.00 |
| Mar 31, 2014 | -5,766.00 |
| Dec 31, 2013 | -9,750.00 |
| Sep 30, 2013 | -6,139.00 |
| Jun 30, 2013 | -6,749.00 |
| Mar 31, 2013 | -5,973.00 |
| Dec 31, 2012 | -9,662.00 |
| Sep 30, 2012 | -6,013.00 |
| Jun 30, 2012 | -6,268.00 |
| Mar 31, 2012 | -5,372.00 |
| Dec 31, 2011 | -8,884.00 |
| Sep 30, 2011 | -6,267.00 |
| Jun 30, 2011 | -6,735.00 |
| Mar 31, 2011 | -5,154.00 |
| Dec 31, 2010 | -7,746.00 |
| Sep 30, 2010 | -4,767.00 |